The year 2016 was a rough one for stock markets. Marked with steep volatility amid sharp corrections with several events — global as well domestic — key share indices saw an almost flat performance throughout the year. Amid this, several equity funds — which are largely international funds — had a phenomenal performance with one-year returns anywhere between 20% and 60%.
On the contrary, there were funds — largely sector-specific ones — which did badly in 2016. A majority of these funds are either pharmaceutical-centric or information technology (IT) funds. For the year, the category average returns of pharma equity